(Tiper Stock Exchange) – Novo Nordiska Danish giant active in the healthcare sector, has closed its first half of 2023 with net sales at 107.7 billion Danish kroner (over €14 billion), up 29% in Danish kroner and 30% at constant exchange rates compared to the same period last year. L’operational profit increased by 30% in Danish kroner and 32% at constant exchange rates to 48.9 billion Danish kroner (over €6 billion).
“We are very satisfied with the sales growth in the first half of 2023 – commented the CEO Lars Fruergaard Jorgensen – Growth is driven by growing demand for our GLP-1-based diabetes and obesity treatments, and we’re serving more patients than ever before. The performance of the first six months has allowed us to improve our prospects for the whole year”.
For the prospects for 2023, sales and operating profit growth at constant exchange rates are now expected to be 27-33% and 31-37%, respectively. Growth in Danish kroner sales and operating profit is expected to be 6 and 9 percentage points lower, respectively, than CER.
The latest announcements about the effectiveness of its drugs have made skyrocketing market value of Novo Nordisk at around $420 billion – more than Denmark’s gross domestic product – and made it the most valuable company in Europe after the French luxury giant LVM extension.